Jonathan R Carapetis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2961344/publications.pdf

Version: 2024-02-01

368 papers 86,251 citations

73 h-index

9786

283 g-index

374 all docs

374 docs citations

times ranked

374

103569 citing authors

#	Article	IF	Citations
1	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	1.8	11
2	Pediatric <i>Staphylococcus aureus</i> Bacteremia: Clinical Spectrum and Predictors of Poor Outcome. Clinical Infectious Diseases, 2022, 74, 604-613.	5.8	13
3	The Spectrum, Severity and Outcomes of Rheumatic Mitral Valve Disease in Pregnant Women in Australia and New Zealand. Heart Lung and Circulation, 2022, 31, 480-490.	0.4	2
4	Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease. New England Journal of Medicine, 2022, 386, 230-240.	27.0	75
5	Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial. Journal of Infectious Diseases, 2022, , .	4.0	4
6	Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association. Journal of the American Heart Association, 2022, 11, e024517.	3.7	5
7	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
8	Improving primary prevention of acute rheumatic fever in Australia: consensus primary care priorities identified through an eDelphi process. BMJ Open, 2022, 12, e056239.	1.9	2
9	Whole genome sequencing and molecular epidemiology of paediatric Staphylococcus aureus bacteraemia. Journal of Global Antimicrobial Resistance, 2022, 29, 197-206.	2.2	6
10	Modelling study of the ability to diagnose acute rheumatic fever at different levels of the Ugandan healthcare system. BMJ Open, 2022, 12, e050478.	1.9	4
11	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	1
12	A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases. Clinical Infectious Diseases, 2022, 75, 1245-1254.	5.8	5
13	Missing Piece Study protocol: prospective surveillance to determine the epidemiology of group A streptococcal pharyngitis and impetigo in remote Western Australia. BMJ Open, 2022, 12, e057296.	1.9	6
14	The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis. EClinicalMedicine, 2022, 48, 101458.	7.1	20
15	Risk factors for group A streptococcal pharyngitis and skin infections: A case control study. The Lancet Regional Health - Western Pacific, 2022, 26, 100507.	2.9	8
16	Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials. Lancet Infectious Diseases, The, 2022, 22, 1374-1387.	9.1	8
17	Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia. Journal of Antimicrobial Chemotherapy, 2022, 77, 2679-2682.	3.0	2
18	<i>Reframe the Behaviour</i> : Evaluation of a training intervention to increase capacity in managing detained youth with fetal alcohol spectrum disorder and neurodevelopmental impairments. Psychiatry, Psychology and Law, 2021, 28, 382-407.	1.2	13

#	Article	IF	CITATIONS
19	Clinical Evaluation and Diagnosis of Acute Rheumatic Fever. , 2021, , 31-54.		2
20	The economic and health burdens of diseases caused by group A Streptococcus in New Zealand. International Journal of Infectious Diseases, 2021, 103, 176-181.	3.3	18
21	Modes of transmission and attack rates of group A Streptococcal infection: a protocol for a systematic review and meta-analysis. Systematic Reviews, 2021, 10, 90.	5. 3	4
22	A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe, The, 2021, 2, e291-e299.	7.3	29
23	Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6Âmonths: PREVIX_COMBO, a 3-arm randomised controlled trial. Vaccine: X, 2021, 7, 100086.	2.1	11
24	Increasing incidence of invasive group A streptococcal disease in Western Australia, particularly among Indigenous people. Medical Journal of Australia, 2021, 215, 36-41.	1.7	10
25	Time to address the neglected burden of group A Streptococcus. Medical Journal of Australia, 2021, 215, 94.	1.7	1
26	Rheumatic heart disease in Indigenous young peoples. The Lancet Child and Adolescent Health, 2021, 5, 437-446.	5 . 6	17
27	High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009399.	3.0	5
28	Global epidemiology of valvular heart disease. Nature Reviews Cardiology, 2021, 18, 853-864.	13.7	217
29	Searching for a technology-driven acute rheumatic fever test: the START study protocol. BMJ Open, 2021, 11, e053720.	1.9	9
30	Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based study. The Lancet Global Health, 2021, 9, e1423-e1430.	6.3	16
31	Comparison of group A streptococcal titres in healthy children and those with pharyngitis and skin infections. Journal of Infection, 2021, , .	3.3	3
32	Rheumatic heart disease in The Gambia: clinical and valvular aspects at presentation and evolution under penicillin prophylaxis. BMC Cardiovascular Disorders, 2021, 21, 503.	1.7	5
33	Long-term outcomes following rheumatic heart disease diagnosis in Australia. European Heart Journal Open, 2021, 1, .	2.3	11
34	Rheumatic Heart Disease in Pregnancy: New Strategies for an Old Disease?. Global Heart, 2021, 16, 84.	2.3	5
35	Caring for Pregnant Women with Rheumatic Heart Disease: A Qualitative Study of Health Service Provider Perspectives. Global Heart, 2021, 16, 88.	2.3	0
36	Group A Streptococcus., 2020,, 429-438.		10

#	Article	IF	CITATIONS
37	Single Parasternal-Long-Axis-View-Sweep Screening Echocardiographic Protocol to Detect Rheumatic Heart Disease: A Prospective Study of Diagnostic Accuracy. Heart Lung and Circulation, 2020, 29, 859-866.	0.4	19
38	The high prevalence and impact of rheumatic heart disease in pregnancy in First Nations populations in a highâ€income setting: a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 47-56.	2.3	17
39	Estimation of the force of infection and infectious period of skin sores in remote Australian communities using interval-censored data. PLoS Computational Biology, 2020, 16, e1007838.	3.2	6
40	Community leadership and empowerment are essential for eliminating rheumatic heart disease. Medical Journal of Australia, 2020, 213, 116-117.	1.7	3
41	Reference exome data for Australian Aboriginal populations to support health-based research. Scientific Data, 2020, 7, 129.	5.3	О
42	Ending rheumatic heart disease in Australia: the evidence for a new approach. Medical Journal of Australia, 2020, 213, S3-S31.	1.7	25
43	Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers. lournal of Antimicrobial Chemotherapy, 2020, 75, 2951-2959.	3.0	14
44	The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. Circulation, 2020, 142, e358-e368.	1.6	30
45	Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Australia Using Linked Data: The Case for Policy Change. Journal of the American Heart Association, 2020, 9, e016851.	3.7	67
46	Active Case Finding for Rheumatic Fever in an Endemic Country. Journal of the American Heart Association, 2020, 9, e016053.	3.7	12
47	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
48	Quality of benzathine penicillin G: A multinational crossâ€sectional study. Pharmacology Research and Perspectives, 2020, 8, e00668.	2.4	5
49	10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial. BMI Open. 2020. 10. e033511.	1.9	4
50	Lessons learned in genetic research with Indigenous Australian participants. Medical Journal of Australia, 2020, 212, 200.	1.7	8
51	Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme: Staphylococcus aureus, enterococcal and Gram-negative bacteraemia in Australia. Journal of Antimicrobial Chemotherapy, 2020, 75, 1639-1644.	3.0	9
52	Cross-sectional study of population-specific streptococcal antibody titres in Uganda. Archives of Disease in Childhood, 2020, 105, 825-829.	1.9	11
53	School-based intervention to address self-regulation and executive functioning in children attending primary schools in remote Australian Aboriginal communities. PLoS ONE, 2020, 15, e0234895.	2.5	20
54	RE-AIM evaluation of a teacher-delivered programme to improve the self-regulation of children attending Australian Aboriginal community primary schools. Emotional and Behavioural Difficulties, 2020, 25, 42-58.	1.2	6

#	Article	IF	CITATIONS
55	Prevalence of group A \hat{l}^2 -hemolytic streptococcal throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan school children. International Journal of Infectious Diseases, 2020, 93, 245-251.	3.3	21
56	Barriers and Enablers of Health Service Utilisation for Childhood Skin Infections in Remote Aboriginal Communities of Western Australia. International Journal of Environmental Research and Public Health, 2020, 17, 808.	2.6	7
57	Continued Challenge of Rheumatic Heart Disease: The Gap of Understanding or the Gap of Implementation?. Global Heart, 2020, 8, 185.	2.3	13
58	Title is missing!. , 2020, 16, e1007838.		0
59	Title is missing!. , 2020, 16, e1007838.		0
60	Title is missing!. , 2020, 16, e1007838.		0
61	Title is missing!. , 2020, 16, e1007838.		0
62	Title is missing!. , 2020, 16, e1007838.		0
63	Title is missing!. , 2020, 16, e1007838.		0
64	The fall and rise of Group A <i>Streptococcus</i> diseases. Epidemiology and Infection, 2019, 147, e4.	2.1	53
65	Seasonal and regional patterns of lower leg cellulitis in Western Australia. Internal Medicine Journal, 2019, 49, 212-216.	0.8	8
66	Inter-rater and intra-rater reliability and agreement of echocardiographic diagnosis of rheumatic heart disease using the World Heart Federation evidence-based criteria. Heart Asia, 2019, 11, e011233.	1.1	20
67	Understanding group A streptococcal pharyngitis and skin infections as causes of rheumatic fever: protocol for a prospective disease incidence study. BMC Infectious Diseases, 2019, 19, 633.	2.9	21
68	Perinatal risk factors associated with skin infection hospitalisation in Western Australian Aboriginal and Nonâ€Aboriginal children. Paediatric and Perinatal Epidemiology, 2019, 33, 374-383.	1.7	4
69	Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nature Genetics, 2019, 51, 1035-1043.	21.4	120
70	Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis. Heart Asia, 2019, 11, e011191.	1.1	16
71	Standardizing clinical care measures of rheumatic heart disease in pregnancy: A qualitative synthesis. Birth, 2019, 46, 560-573.	2.2	2
72	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine, 2019, 37, 3485-3494.	3.8	31

#	Article	IF	CITATIONS
73	A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies. Journal of Antimicrobial Chemotherapy, 2019, 74, 1984-1991.	3.0	16
74	Low positive predictive value of International Classification of Diseases, 10th Revision codes in relation to rheumatic heart disease: a challenge for global surveillance. Internal Medicine Journal, 2019, 49, 400-403.	0.8	19
75	Environmental and social determinants of acute rheumatic fever: a longitudinal cohort study. Epidemiology and Infection, 2019, 147, e79.	2.1	4
76	High burden of infectious disease and antibiotic use in early life in Australian Aboriginal communities. Australian and New Zealand Journal of Public Health, 2019, 43, 149-155.	1.8	11
77	SToP (See, Treat, Prevent) skin sores and scabies trial: study protocol for a cluster randomised, stepped-wedge trial for skin disease control in remote Western Australia. BMJ Open, 2019, 9, e030635.	1.9	13
78	The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis. BMJ Open, 2019, 9, e032549.	1.9	11
79	Time to tackle rheumatic heart disease: Data needed to drive global policy dialogues. Global Public Health, 2019, 14, 456-468.	2.0	7
80	Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Tropical Medicine and International Health, 2019, 24, 280-293.	2.3	27
81	Impact of heart disease on maternal, fetal and neonatal outcomes in a low-resource setting. Heart, 2019, 105, 755-760.	2.9	40
82	The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. Clinical Infectious Diseases, 2019, 69, 877-883.	5.8	122
83	Talking skin: attitudes and practices around skin infections, treatment options, and their clinical management in a remote region in Western Australia. Rural and Remote Health, 2019, 19, 5227.	0.5	6
84	Epidemiology and risk factors for recurrent severe lower limb cellulitis: a longitudinal cohort study. Clinical Microbiology and Infection, 2018, 24, 1084-1088.	6.0	18
85	Severe lower limb cellulitis: defining the epidemiology and risk factors for primary episodes in a population-based case-control study. Clinical Microbiology and Infection, 2018, 24, 1089-1094.	6.0	23
86	Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). Drug Delivery and Translational Research, 2018, 8, 729-739.	5 . 8	11
87	Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant Staphylococcus aureus clone reveals discrepant resistance reporting. Clinical Microbiology and Infection, 2018, 24, 1027-1029.	6.0	15
88	Rheumatic heart disease in pregnancy: How can health services adapt to the needs of Indigenous women? A qualitative study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 425-431.	1.0	19
89	Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 137-149.	2.3	63
90	Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia. Pneumonia (Nathan Qld), 2018, 10, 13.	6.1	7

#	Article	IF	CITATIONS
91	Dysregulated IL- $\hat{1}^2$ -GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine. Circulation, 2018, 138, 2648-2661.	1.6	33
92	Australian researchers oppose funding from the Foundation for a Smokeâ€Free World. Australian and New Zealand Journal of Public Health, 2018, 42, 506-507.	1.8	3
93	How Many Doses Make a Difference? An Analysis of Secondary Prevention of Rheumatic Fever and Rheumatic Heart Disease. Journal of the American Heart Association, 2018, 7, e010223.	3.7	48
94	Ascertaining infectious disease burden through primary care clinic attendance among young Aboriginal children living in four remote communities in Western Australia. PLoS ONE, 2018, 13, e0203684.	2.5	20
95	The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children. BMJ Open, 2018, 8, e019632.	1.9	10
96	An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine, 2018, 36, 6968-6978.	3.8	41
97	Rheumatic Heart Disease Worldwide. Journal of the American College of Cardiology, 2018, 72, 1397-1416.	2.8	137
98	Calculation of the age of the first infection for skin sores and scabies in five remote communities in northern Australia. Epidemiology and Infection, 2018, 146, 1194-1201.	2.1	9
99	Primary prevention of rheumatic fever in the 21st century: evaluation of a national programme. International Journal of Epidemiology, 2018, 47, 1585-1593.	1.9	32
100	Scabies and risk of skin sores in remote Australian Aboriginal communities: A self-controlled case series study. PLoS Neglected Tropical Diseases, 2018, 12, e0006668.	3.0	13
101	Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 2018, 13, e0198658.	2.5	59
102	Improving Delivery of Secondary Prophylaxis for Rheumatic Heart Disease in a Highâ€Burden Setting: Outcome of a Steppedâ€Wedge, Community, Randomized Trial. Journal of the American Heart Association, 2018, 7, .	3.7	30
103	Qualitative Evaluation of a Complex Intervention to Improve Rheumatic Heart Disease Secondary Prophylaxis. Journal of the American Heart Association, 2018, 7, .	3.7	21
104	Development of an opsonophagocytic killing assay for group a streptococcus. Vaccine, 2018, 36, 3756-3763.	3.8	23
105	Rheumatic heart disease in Timorâ€Leste school students: an echocardiographyâ€based prevalence study. Medical Journal of Australia, 2018, 208, 303-307.	1.7	25
106	Fetal Alcohol Spectrum Disorder (FASD): Knowledge, attitudes, experiences and practices of the Western Australian youth custodial workforce. International Journal of Law and Psychiatry, 2018, 59, 44-52.	0.9	37
107	Rheumatic Heart Disease Severity, Progression and Outcomes: A Multiâ€State Model. Journal of the American Heart Association, 2017, 6, .	3.7	57
108	Echocardiographic Screening for Rheumatic Heart Disease in Indigenous Australian Children: A Cost–Utility Analysis. Journal of the American Heart Association, 2017, 6, .	3.7	34

#	Article	IF	CITATIONS
109	Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji. International Journal of Cardiology, 2017, 240, 422-427.	1.7	20
110	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	2.8	2,705
111	Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness. Vaccine, 2017, 35, 2908-2915.	3 . 8	15
112	Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 15.	0.9	97
113	Clinical development strategy for a candidate group A streptococcal vaccine. Vaccine, 2017, 35, 2007-2014.	3.8	18
114	Rheumatic heart disease across the Western Pacific: not just a Pacific Island problem. Heart Asia, 2017, 9, e010948.	1,1	7
115	Genome-Wide Analysis of Genetic Risk Factors for Rheumatic Heart Disease in Aboriginal Australians Provides Support for Pathogenic Molecular Mimicry. Journal of Infectious Diseases, 2017, 216, 1460-1470.	4.0	60
116	Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. New England Journal of Medicine, 2017, 377, 713-722.	27.0	771
117	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
118	Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infectious Diseases, 2017, 4, ofx232.	0.9	42
119	Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data. PLoS ONE, 2017, 12, e0178264.	2.5	17
120	Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012. PLoS ONE, 2017, 12, e0188803.	2.5	17
121	Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community. PLoS Neglected Tropical Diseases, 2017, 11, e0005607.	3.0	51
122	Rheumatic heart disease: infectious disease origin, chronic care approach. BMC Health Services Research, 2017, 17, 793.	2.2	37
123	Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet Journal of Rare Diseases, 2017, 12, 83.	2.7	24
124	The inequitable burden of group A streptococcal diseases in Indigenous Australians. Medical Journal of Australia, 2016, 205, 201-203.	1.7	44
125	The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo. Pediatric Infectious Disease Journal, 2016, 35, 374-378.	2.0	23
126	Impetigo and scabies – Disease burden and modern treatment strategies. Journal of Infection, 2016, 72, S61-S67.	3.3	32

#	Article	IF	Citations
127	Status of research and development of vaccines for Streptococcus pyogenes. Vaccine, 2016, 34, 2953-2958.	3.8	113
128	Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial. Vaccine, 2016, 34, 4991-4997.	3.8	11
129	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
130	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
131	A systematic review of the evidence that swimming pools improve health and wellbeing in remote Aboriginal communities in Australia. Australian and New Zealand Journal of Public Health, 2016, 40, 30-36.	1.8	20
132	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Delivery and Translational Research, 2016, 6, 572-578.	5.8	24
133	Transiently increased IgE responses in infants and pre-schoolers receiving only acellular Diphtheria–Pertussis–Tetanus (DTaP) vaccines compared to those initially receiving at least one dose of cellular vaccine (DTwP) – Immunological curiosity or canary in the mine?. Vaccine, 2016, 34, 4257-4262.	3.8	13
134	Long-Term Outcomes From Acute Rheumatic Fever and Rheumatic Heart Disease. Circulation, 2016, 134, 222-232.	1.6	66
135	Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. Systematic Reviews, 2016, 5, 162.	5.3	11
136	Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers, 2016, 2, 15084.	30.5	371
137	Focused cardiac ultrasound screening for rheumatic heart disease by briefly trained health workers: a study of diagnostic accuracy. The Lancet Global Health, 2016, 4, e386-e394.	6.3	59
138	Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trial. Trials, 2016, 17, 51.	1.6	25
139	Screening for rheumatic heart disease: quality and agreement of focused cardiac ultrasound by briefly trained health workers. BMC Cardiovascular Disorders, 2016, 16, 30.	1.7	31
140	Whole genome sequencing reveals extensive community-level transmission of group A <i>Streptococcus</i> i>in remote communities. Epidemiology and Infection, 2016, 144, 1991-1998.	2.1	19
141	Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease. IDCases, 2016, 4, 6-7.	0.9	5
142	Development of Group A streptococcal vaccines: an unmet global health need. Expert Review of Vaccines, 2016, 15, 227-238.	4.4	23
143	Towards Improving Point-of-Care Diagnosis of Non-malaria Febrile Illness: A Metabolomics Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004480.	3.0	16
144	Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqu \tilde{A} ©. Cardiovascular Journal of Africa, 2016, 27, 184-1847.	0.4	104

#	Article	IF	Citations
145	Comparison of approaches to rheumatic fever surveillance across <scp>O</scp> rganisation for <scp>E</scp> conomic <scp>C</scp> oâ€operation and Development countries. Journal of Paediatrics and Child Health, 2015, 51, 1071-1077.	0.8	7
146	Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community. PLoS Neglected Tropical Diseases, 2015, 9, e0004151.	3.0	81
147	The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS ONE, 2015, 10, e0136789.	2.5	207
148	Rheumatic heart disease in Indigenous children in northern Australia: differences in prevalence and the challenges of screening. Medical Journal of Australia, 2015, 203, 221-221.	1.7	36
149	Controlling acute rheumatic fever and rheumatic heart disease in developing countries. Current Opinion in Pediatrics, 2015, 27, 116-123.	2.0	33
150	The prevention, diagnosis and management of central venous line infections in children. Journal of Infection, 2015, 71, S59-S75.	3.3	58
151	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
152	The stark reality of rheumatic heart disease. European Heart Journal, 2015, 36, 1070-1073.	2.2	27
153	Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. BMJ Open, 2015, 5, e007247-e007247.	1.9	22
154	Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians. Journal of the American Heart Association, 2015, 4, .	3.7	21
155	Changes in the clinical and epidemiological features of group <scp>A</scp> streptococcal bacteraemia in <scp>A</scp> ustralia's <scp>N</scp> orthern <scp>T</scp> erritory. Tropical Medicine and International Health, 2015, 20, 40-47.	2.3	24
156	Prevalence of rheumatic heart disease in young adults from New Caledonia. Archives of Cardiovascular Diseases, 2015, 108, 16-22.	1.6	13
157	Are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease?. International Journal of Cardiology, 2015, 198, 117-122.	1.7	53
158	Reply to Banderet-Uglioni et al. Clinical Infectious Diseases, 2015, 60, 323-324.	5. 8	0
159	Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. Circulation, 2015, 131, 1806-1818.	1.6	515
160	Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmunity Reviews, 2015, 14, 710-725.	5.8	91
161	Pediatric sepsis in the developing world. Journal of Infection, 2015, 71, S21-S26.	3.3	39
162	Sore throat: Is it such a big deal anymore?. Journal of Infection, 2015, 71, S101-S105.	3.3	8

#	Article	IF	CITATIONS
163	The 2015 revision of the Jones criteria for the diagnosis of acute rheumatic fever: implications for practice in low-income and middle-income countries. Heart Asia, 2015, 7, 7-11.	1.1	33
164	Rheumatic Fever: What is New?. Current Pediatrics Reports, 2015, 3, 211-218.	4.0	1
165	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
166	PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia. Vaccine, 2015, 33, 6579-6587.	3.8	27
167	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	13.7	5,847
168	Evolution, evidence and effect of secondary prophylaxis against rheumatic fever. Journal of the Practice of Cardiovascular Sciences, $2015, 1, 9$.	0.1	7
169	Standardising and Assessing Digital Images for Use in Clinical Trials: A Practical, Reproducible Method That Blinds the Assessor to Treatment Allocation. PLoS ONE, 2014, 9, e110395.	2.5	14
170	The case for global investment in rheumatic heart-disease control. Bulletin of the World Health Organization, 2014, 92, 768-770.	3.3	26
171	Management of invasive group A streptococcal infections. Journal of Infection, 2014, 69, S63-S69.	3.3	38
172	The microbiology of impetigo in Indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage. BMC Infectious Diseases, 2014, 14, 727.	2.9	104
173	Echocardiographic Screening for Rheumatic Heart Disease in High and Low Risk Australian Children. Circulation, 2014, 129, 1953-1961.	1.6	99
174	Invasive Staphylococcus aureus Infections in Children in Tropical Northern Australia. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 304-311.	1.3	22
175	Susceptibility to Acute Rheumatic Fever Based on Differential Expression of Genes Involved in Cytotoxicity, Chemotaxis, and Apoptosis. Infection and Immunity, 2014, 82, 753-761.	2.2	16
176	Reply to Letter Regarding Article, "Acute Rheumatic Fever and Rheumatic Heart Disease: Incidence and Progression in the Northern Territory of Australia, 1997 to 2010― Circulation, 2014, 129, e397.	1.6	1
177	Invasive group <scp>A</scp> streptococcal infection in the <scp>N</scp> orthern <scp>T</scp> erritory, <scp>A</scp> ustralia: Case report and review of the literature. Journal of Paediatrics and Child Health, 2014, 50, 869-873.	0.8	9
178	O070 Echocardiographic screening for rheumatic heart disease in high-risk and low-risk children: results of the Australian gECHO study., 2014, 9, e19.		1
179	A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development. Journal of Infectious Diseases, 2014, 210, 1325-1338.	4.0	257
180	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	13.7	609

#	Article	IF	CITATIONS
181	Effectiveness of Clindamycin and Intravenous Immunoglobulin, and Risk of Disease in Contacts, in Invasive Group A Streptococcal Infections. Clinical Infectious Diseases, 2014, 59, 358-365.	5.8	195
182	Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet, The, 2014, 384, 2132-2140.	13.7	96
183	The clinical and molecular epidemiology of Staphylococcus aureus infections in Fiji. BMC Infectious Diseases, 2014, 14, 160.	2.9	49
184	Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop. Vaccine, 2014, 32, 3713-3720.	3.8	44
185	Echocardiographic screening in a resource poor setting: Borderline rheumatic heart disease could be a normal variant. International Journal of Cardiology, 2014, 173, 284-289.	1.7	35
186	Formal Infectious Diseases Consultations at a Tertiary Pediatric Hospital. Pediatric Infectious Disease Journal, 2014, 33, 411-413.	2.0	9
187	Acute Rheumatic Fever and Chronic Rheumatic Disease. , 2014, , 2329-2350.		1
188	Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nature Reviews Cardiology, 2013, 10, 284-292.	13.7	224
189	Screening for rheumatic heart disease: current approaches and controversies. Nature Reviews Cardiology, 2013, 10, 49-58.	13.7	106
190	Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach. BMC Health Services Research, 2013, 13, 525.	2.2	42
191	ABRACADABRA aids Indigenous and non-Indigenous early literacy in Australia: Evidence from a multisite randomized controlled trial. Computers and Education, 2013, 67, 250-264.	8.3	30
192	Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine, 2013, 31, B216-B222.	3.8	79
193	Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clinical Microbiology and Infection, 2013, 19, E222-E229.	6.0	135
194	Reply to "Susceptibility of Streptococcus pyogenes to Trimethoprim-Sulfamethoxazole― Journal of Clinical Microbiology, 2013, 51, 1351-1351.	3.9	0
195	Comparison of three methods for the recovery of skin pathogens from impetigo swabs collected in a remote community of Northern Territory, Australia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 384-389.	1.8	8
196	Acute Rheumatic Fever and Rheumatic Heart Disease. Circulation, 2013, 128, 492-501.	1.6	183
197	Preventing Urinary Tract Infections in Early Childhood. Advances in Experimental Medicine and Biology, 2013, 764, 211-218.	1.6	19
198	Pilot study of nurse-led rheumatic heart disease echocardiography screening in Fiji – a novel approach in a resource-poor setting. Cardiology in the Young, 2013, 23, 546-552.	0.8	55

#	Article	IF	Citations
199	Commentary on <scp>R</scp>emond <i>et al</i>. . Journal of Paediatrics and Child Health, 2013, 49, 532-534.	0.8	0
200	Progress Toward a Global Group A Streptococcal Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 180-182.	2.0	38
201	A National Prospective Surveillance Study of Acute Rheumatic Fever in Australian Children. Pediatric Infectious Disease Journal, 2013, 32, e26-e32.	2.0	33
202	Group A Streptococcus., 2013,, 391-401.		2
203	Clinic Attendances during the First 12 Months of Life for Aboriginal Children in Five Remote Communities of Northern Australia. PLoS ONE, 2013, 8, e58231.	2.5	61
204	Extensive Diversity of Streptococcus pyogenes in a Remote Human Population Reflects Global-Scale Transmission Rather than Localised Diversification. PLoS ONE, 2013, 8, e73851.	2.5	21
205	Utility of auscultatory screening for detecting rheumatic heart disease in highâ€risk children in Australia's Northern Territory. Medical Journal of Australia, 2013, 199, 196-199.	1.7	43
206	The Second Rheumatic Heart Disease Forum Report. Global Heart, 2013, 8, 253.	2.3	11
207	Is Streptococcus pyogenes Resistant or Susceptible to Trimethoprim-Sulfamethoxazole?. Journal of Clinical Microbiology, 2012, 50, 4067-4072.	3.9	52
208	Trough Concentrations of Vancomycin. Pediatric Infectious Disease Journal, 2012, 31, 1269-1271.	2.0	41
209	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
210	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	13.7	11,038
211	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
212	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
213	Rheumatic Fever Follow-Up Study (RhFFUS) protocol: a cohort study investigating the significance of minor echocardiographic abnormalities in Aboriginal Australian and Torres Strait Islander children. BMC Cardiovascular Disorders, 2012, 12, 111.	1.7	4
214	Use of health services by remote dwelling Aboriginal infants in tropical northern Australia: a retrospective cohort study. BMC Pediatrics, 2012, 12, 19.	1.7	25
215	World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nature Reviews Cardiology, 2012, 9, 297-309.	13.7	604
216	Invasive Group A Streptococcal Disease. Drugs, 2012, 72, 1213-1227.	10.9	169

#	Article	IF	Citations
217	Group A Streptococcal Diseases and Their Global Burden. Current Topics in Microbiology and Immunology, 2012, 368, 1-27.	1.1	231
218	The future of acute rheumatic fever and rheumatic heart disease in Australia. Medical Journal of Australia, 2012, 197, 133-134.	1.7	19
219	Rotavirus infection in Northern Territory before and after vaccination. Microbiology Australia, 2012, 33, 61.	0.4	10
220	Community-associated Methicillin-resistant Staphylococcus aureus Skin Infections in the Tropics. Dermatologic Clinics, 2011, 29, 21-32.	1.7	22
221	Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine, 2011, 29, 535-544.	3.8	28
222	Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine, 2011, 29, 4499-4506.	3.8	14
223	Defining and Assessing the School Readiness of Indigenous Australian Children. Australasian Journal of Early Childhood, 2011, 36, 69-76.	1.0	16
224	Trial of a developmental screening tool in remote Australian Aboriginal communities: A cautionary tale. Journal of Paediatrics and Child Health, 2011, 47, 12-17.	0.8	26
225	Persistence of acute rheumatic fever in a tertiary children's hospital. Journal of Paediatrics and Child Health, 2011, 47, 198-203.	0.8	24
226	East African immigrant children in Australia have poor immunisation coverage. Journal of Paediatrics and Child Health, 2011, 47, 888-892.	0.8	38
227	Skin disease in the first two years of life in Aboriginal children in East Arnhem Land. Australasian Journal of Dermatology, 2011, 52, 270-273.	0.7	43
228	Preliminary validation of a novel high-resolution melt-based typing method based on the multilocus sequence typing scheme of Streptococcus pyogenes. Clinical Microbiology and Infection, 2011, 17, 1426-1434.	6.0	19
229	Secondary Prophylaxis is Important for the Prevention of Recurrent Rheumatic Fever in the Pacific. Pediatric Cardiology, 2011, 32, 864-865.	1.3	4
230	Case-Control Evaluation of the Effectiveness of the G1P[8] Human Rotavirus Vaccine during an Outbreak of Rotavirus G2P[4] Infection in Central Australia. Clinical Infectious Diseases, 2011, 52, 191-199.	5.8	91
231	Global research priorities in rheumatic fever and rheumatic heart disease. Annals of Pediatric Cardiology, 2011, 4, 4.	0.5	62
232	Advances in the Diagnosis and Management of Central Venous Access Device Infections in Children. Advances in Experimental Medicine and Biology, 2011, 697, 91-106.	1.6	11
233	Prevention of Rheumatic Fever. Pediatric Infectious Disease Journal, 2010, 29, 91-92.	2.0	26
234	Invasive Pneumococcal Disease in Fiji. Pediatric Infectious Disease Journal, 2010, 29, 870-872.	2.0	14

#	Article	IF	Citations
235	Parasitic diseases of remote Indigenous communities in Australia. International Journal for Parasitology, 2010, 40, 1119-1126.	3.1	41
236	Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infectious Diseases, 2010, 10, 304.	2.9	131
237	Trimethoprimâ€sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: A pilot randomised controlled trial. Journal of Paediatrics and Child Health, 2010, 46, 131-133.	0.8	24
238	Rheumatic fever in Indigenous Australian children. Journal of Paediatrics and Child Health, 2010, 46, 527-533.	0.8	107
239	Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster. Vaccine Journal, 2010, 17, 1970-1976.	3.1	62
240	Comparison of Citrated Human Blood, Citrated Sheep Blood, and Defibrinated Sheep Blood Mueller-Hinton Agar Preparations for Antimicrobial Susceptibility Testing of <i>Streptococcus pneumoniae</i> Isolates. Journal of Clinical Microbiology, 2010, 48, 3770-3772.	3.9	7
241	Letter by Carapetis Regarding Article, "ls Primary Prevention of Rheumatic Fever the Missing Link in the Control of Rheumatic Heart Disease in Africa?― Circulation, 2010, 121, e384; author reply e385.	1.6	8
242	Treatment of Group A streptococcal infections. Paediatrics and Child Health (United Kingdom), 2010, 20, 513-520.	0.4	1
243	Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia. Vaccine, 2010, 28, 2296-2301.	3.8	15
244	Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine, 2010, 28, 3086-3094.	3.8	31
245	Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine, 2010, 28, 3341-3349.	3.8	71
246	Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote Northern Territory Indigenous communities: Implications for vaccine development. Vaccine, 2010, 28, 5301-5305.	3.8	16
247	High Burden of Impetigo and Scabies in a Tropical Country. PLoS Neglected Tropical Diseases, 2009, 3, e467.	3.0	121
248	Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance, 2005–2007. Medical Journal of Australia, 2009, 190, 133-135.	1.7	65
249	Prevention and treatment of rheumatic heart disease in the developing world. Nature Reviews Cardiology, 2009, 6, 689-698.	13.7	69
250	Rheumatic heart disease and its control in the Pacific. Expert Review of Cardiovascular Therapy, 2009, 7, 1517-1524.	1.5	26
251	Prospective Surveillance of Invasive Group A Streptococcal Disease, Fiji, 2005–2007. Emerging Infectious Diseases, 2009, 15, 216-222.	4.3	35
252	A Regional Initiative to Reduce Skin Infections amongst Aboriginal Children Living in Remote Communities of the Northern Territory, Australia. PLoS Neglected Tropical Diseases, 2009, 3, e554.	3.0	93

#	Article	IF	Citations
253	Community Management of Endemic Scabies in Remote Aboriginal Communities of Northern Australia: Low Treatment Uptake and High Ongoing Acquisition. PLoS Neglected Tropical Diseases, 2009, 3, e444.	3.0	79
254	Normal Ranges of Streptococcal Antibody Titers Are Similar Whether Streptococci Are Endemic to the Setting or Not. Vaccine Journal, 2009, 16, 172-175.	3.1	50
255	<i>emm</i> and C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development. Journal of Clinical Microbiology, 2009, 47, 2502-2509.	3.9	52
256	Rotavirus and the Indigenous Children of the Australian Outback: Monovalent Vaccine Effective in a Highâ∈Burden Setting. Clinical Infectious Diseases, 2009, 49, 428-431.	5.8	64
257	Some of the People, Some of the Time. Circulation, 2009, 119, 742-753.	1.6	137
258	Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. BMC Pediatrics, 2009, 9, 14.	1.7	53
259	Underdiagnosis of acute rheumatic fever in primary care settings in a developing country. Tropical Medicine and International Health, 2009, 14, 1407-1413.	2.3	27
260	Joining the dots: The links between education and health and implications for Indigenous children. Journal of Paediatrics and Child Health, 2009, 45, 692-697.	0.8	11
261	Group A streptococcal vaccines: facts versus fantasy. Current Opinion in Infectious Diseases, 2009, 22, 544-552.	3.1	92
262	Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine, 2009, 27, 5685-5691.	3.8	58
263	Antibiotic Prophylaxis and Recurrent Urinary Tract Infection in Children. New England Journal of Medicine, 2009, 361, 1748-1759.	27.0	409
264	Skin Disorders, Including Pyoderma, Scabies, and Tinea Infections. Pediatric Clinics of North America, 2009, 56, 1421-1440.	1.8	75
265	Acute Rheumatic Fever and Rheumatic Heart Disease in Indigenous Populations. Pediatric Clinics of North America, 2009, 56, 1401-1419.	1.8	38
266	Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infectious Diseases, The, 2009, 9, 611-616.	9.1	439
267	Prospective Surveillance of Streptococcal Sore Throat in a Tropical Country. Pediatric Infectious Disease Journal, 2009, 28, 477-482.	2.0	53
268	Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji. Bulletin of the World Health Organization, 2009, 87, 173-179.	3.3	62
269	Ivermectin worthy of further investigation. Bulletin of the World Health Organization, 2009, 87, A-B.	3.3	17
270	Prospective Surveillance of Invasive Group A Streptococcal Disease, Fiji, 2005–2007. Emerging Infectious Diseases, 2009, 15, 216-222.	4.3	30

#	Article	IF	Citations
271	High prevalence of rheumatic heart disease by clinical and echocardiographic screening among children in Fiji. Journal of Heart Valve Disease, 2009, 18, 327-35; discussion 336.	0.5	55
272	The Diagnosis and Management of Chronic Rheumatic Heart Diseaseâ€"An Australian Guideline. Heart Lung and Circulation, 2008, 17, 271-289.	0.4	11
273	Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population. Vaccine, 2008, 26, 3885-3891.	3.8	15
274	The high burden of rheumatic heart disease found on autopsy in Fiji. Cardiology in the Young, 2008, 18, 62-9.	0.8	17
275	Rheumatic Heart Disease in Asia. Circulation, 2008, 118, 2748-2753.	1.6	94
276	Diagnosis and treatment of invasive group A streptococcal infections. Expert Opinion on Medical Diagnostics, 2008, 2, 289-301.	1.6	7
277	Superantigen genes in group A streptococcal isolates and their relationship with emm types. Journal of Medical Microbiology, 2008, 57, 1238-1246.	1.8	53
278	Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 411-417.	3.3	148
279	Disease burden and health-care climic attendances for young children in remote Aboriginal communities of northern Australia. Bulletin of the World Health Organization, 2008, 86, 275-281.	3.3	122
280	Pediatric rheumatic heart disease in the developing world: echocardiographic versus clinical screening. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 74-75.	3.3	14
281	The dynamic nature of group A streptococcal epidemiology in tropical communities with high rates of rheumatic heart disease. Epidemiology and Infection, 2008, 136, 529-539.	2.1	36
282	High burden of invasive $\langle i \rangle \hat{l}^2 \langle i \rangle$ -haemolytic streptococcal infections in Fiji. Epidemiology and Infection, 2008, 136, 621-627.	2.1	36
283	The need for a global perspective on heart valve disease epidemiology. The SHVD working group on epidemiology of heart valve disease founding statement. Journal of Heart Valve Disease, 2008, 17, 135-9.	0.5	25
284	Acute rheumatic fever: an important differential diagnosis of septic arthritis. Journal of Tropical Pediatrics, 2007, 54, 205-207.	1.5	10
285	Rheumatic Heart Disease in Developing Countries. New England Journal of Medicine, 2007, 357, 439-441.	27.0	236
286	Burden of Acute Sore Throat and Group A Streptococcal Pharyngitis in School-aged Children and Their Families in Australia. Pediatrics, 2007, 120, 950-957.	2.1	98
287	Community Epidemiology of Human Metapneumovirus, Human Coronavirus NL63, and Other Respiratory Viruses in Healthy Preschool-Aged Children Using Parent-Collected Specimens. Pediatrics, 2007, 120, e929-e937.	2.1	127
288	High prevalence of asymptomatic vitamin D and iron deficiency in East African immigrant children and adolescents living in a temperate climate. Archives of Disease in Childhood, 2007, 92, 1088-1093.	1.9	83

#	Article	IF	Citations
289	Strain Prevalence, Rather than Innate Virulence Potential, Is the Major Factor Responsible for an Increase in Serious Group A Streptococcus Infections. Journal of Infectious Diseases, 2007, 195, 1625-1633.	4.0	63
290	Molecular typing of Streptococcus pyogenes from remote Aboriginal communities where rheumatic fever is common and pyoderma is the predominant streptococcal infection. Epidemiology and Infection, 2007, 135, 1398-1405.	2.1	41
291	Indirect effects of childhood pneumococcal vaccination on pneumococcal carriage among adults and older children in Australian Aboriginal communities. Vaccine, 2007, 25, 2428-2433.	3.8	10
292	Subclinical carditis in rheumatic fever: A systematic review. International Journal of Cardiology, 2007, 119, 54-58.	1.7	75
293	Apparent Contrasting Rates of Pharyngitis and Pyoderma in Regions where Rheumatic Heart Disease is Highly Prevalent. Heart Lung and Circulation, 2007, 16, 254-259.	0.4	28
294	Epidemiology of <i> Streptococcus dysgalactiae </i> > subsp. <i> equisimilis </i> > in Tropical Communities, Northern Australia. Emerging Infectious Diseases, 2007, 13, 1694-1700.	4.3	51
295	An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. Medical Journal of Australia, 2007, 186, 581-586.	1.7	65
296	The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Medical Journal of Australia, 2007, 186, 565-569.	1.7	72
297	Group A streptococcal infections in children. Journal of Paediatrics and Child Health, 2007, 43, 203-213.	0.8	117
298	Practical challenges of conducting research into rheumatic fever in remote Aboriginal communities. Medical Journal of Australia, 2006, 184, 511-513.	1.7	8
299	Bâ€cell antigen D8/17 is a marker of rheumatic fever susceptibility in Aboriginal Australians and can be tested in remote settings. Medical Journal of Australia, 2006, 184, 507-510.	1.7	19
300	The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. BMJ: British Medical Journal, 2006, 332, 733.	2.3	2
301	Pneumococcal nasopharyngeal carriage and patterns of penicillin resistance in young children in Fiji. Annals of Tropical Paediatrics, 2006, 26, 187-197.	1.0	30
302	Low Rates of Streptococcal Pharyngitis and High Rates of Pyoderma in Australian Aboriginal Communities Where Acute Rheumatic Fever Is Hyperendemic. Clinical Infectious Diseases, 2006, 43, 683-689.	5.8	175
303	Recovering Streptococci from the Throat, a Practical Alternative to Direct Plating in Remote Tropical Communities. Journal of Clinical Microbiology, 2006, 44, 547-552.	3.9	25
304	Use of a Single-Nucleotide Polymorphism Genotyping System To Demonstrate the Unique Epidemiology of Methicillin-Resistant Staphylococcus aureus in Remote Aboriginal Communities. Journal of Clinical Microbiology, 2006, 44, 3720-3727.	3.9	113
305	As a Bacterial Culture Medium, Citrated Sheep Blood Agar Is a Practical Alternative to Citrated Human Blood Agar in Laboratories of Developing Countries. Journal of Clinical Microbiology, 2006, 44, 3346-3351.	3.9	63
306	Antibiotic Prophylaxis for the Prevention of Recurrent Urinary Tract Infections in Children., 2006, 582, 243-249.		0

#	Article	IF	Citations
307	The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. South African Medical Journal, 2006, 96, 246.	0.6	63
308	Control of rheumatic heart disease in the Pacific region. Pacific Health Dialog: A Publication of the Pacific Basin Officers Training Program and the Fiji School of Medicine, 2006, 13, 49-55.	0.2	11
309	Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. Journal of Paediatrics and Child Health, 2005, 41, 201-208.	0.8	9
310	New normal ranges of antistreptolysin O and antideoxyribonuclease B titres for Australian children. Journal of Paediatrics and Child Health, 2005, 41, 583-586.	0.8	31
311	The clinical course of acute otitis media in high-risk Australian Aboriginal children: a longitudinal study. BMC Pediatrics, 2005, 5, 16.	1.7	29
312	A pilot study of the quality of informed consent materials for Aboriginal participants in clinical trials. Journal of Medical Ethics, 2005, 31, 490-494.	1.8	16
313	Preventing recurrent rheumatic fever: the role of register based programmes. Heart, 2005, 91, 1131-1133.	2.9	55
314	Acute rheumatic fever. Lancet, The, 2005, 366, 155-168.	13.7	525
315	Acute rheumatic fever – Authors' reply. Lancet, The, 2005, 366, 1355-1356.	13.7	31
316	The global burden of group A streptococcal diseases. Lancet Infectious Diseases, The, 2005, 5, 685-694.	9.1	2,384
317	Frequently asked questions about varicella vaccine. Australian Prescriber, 2005, 28, 2-5.	1.0	1
318	Group A Streptococci from a Remote Community Have Novel Multilocus Genotypes but ShareemmTypes and Housekeeping Alleles with Isolates from Worldwide Sources. Journal of Infectious Diseases, 2004, 189, 717-723.	4.0	72
319	Prospective Study of a Real-Time PCR That Is Highly Sensitive, Specific, and Clinically Useful for Diagnosis of Meningococcal Disease in Children. Journal of Clinical Microbiology, 2004, 42, 2919-2925.	3.9	79
320	Acute Hematogenous Osteomyelitis in Children. Paediatric Drugs, 2004, 6, 333-346.	3.1	47
321	The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine, 2004, 23, 755-761.	3.8	35
322	Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infectious Diseases, The, 2004, 4, 240-245.	9.1	237
323	Current Issues in Managing Group A Streptococcal Infections. Advances in Experimental Medicine and Biology, 2004, 549, 185-190.	1.6	7
324	Demographics and utilisation of health services by paediatric refugees from East Africa: implications for service planning and provision. Australian Health Review, 2004, 27, 40.	1.1	9

#	Article	IF	Citations
325	The burden of group A streptococcal pharyngitis in Melbourne families. Indian Journal of Medical Research, 2004, 119 Suppl, 144-7.	1.0	11
326	<i>Streptococcus pyogenes</i> recruits collagen via surfaceâ€bound fibronectin: a novel colonization and immune evasion mechanism. Molecular Microbiology, 2003, 47, 861-869.	2.5	69
327	Screening for intestinal parasites in recently arrived children from East Africa. Journal of Paediatrics and Child Health, 2003, 39, 456-459.	0.8	25
328	Missed opportunities for a diagnosis of acute otitis media in Aboriginal children. Journal of Paediatrics and Child Health, 2003, 39, 540-542.	0.8	2
329	Serotypes of respiratory tract isolates of Streptococcus pneumoniae from Jamaican children. International Journal of Infectious Diseases, 2003, 7, 29-34.	3.3	6
330	High Incidence of Haemophilus influenzae Type b Infection in Children in Pacific Island Countries. Clinical Infectious Diseases, 2003, 37, 1593-1599.	5.8	18
331	Recurrent crepitant cellulitis caused by Clostridium perfringens. Pediatric Infectious Disease Journal, 2002, 21, 1173-1174.	2.0	10
332	Impact of single dose azithromycin on group A streptococci in the upper respiratory tract and skin of Aboriginal children. Pediatric Infectious Disease Journal, 2002, 21, 375-380.	2.0	26
333	The "surreptitious staphylococcusâ€staphylococcus lugdunensis endocarditis in a child. Pediatric Infectious Disease Journal, 2002, 21, 984-986.	2.0	33
334	Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children. Pediatric Infectious Disease Journal, 2002, 21, 935-939.	2.0	9
335	Privacy legislation and research. Medical Journal of Australia, 2002, 177, 523-523.	1.7	8
336	Treatment of sore throat in light of the Cochrane verdict: is the jury still out?. Medical Journal of Australia, 2002, 177, 512-515.	1.7	21
337	Duration of antibiotics in children with osteomyelitis and septic arthritis. Journal of Paediatrics and Child Health, 2002, 38, 363-367.	0.8	61
338	Childhood invasive pneumococcal disease in Tasmania, 1994-2000. Journal of Paediatrics and Child Health, 2002, 38, 445-449.	0.8	3
339	Systematic review of rheumatic heart disease prevalencein children in developing countries: The role of environmental factors. Journal of Paediatrics and Child Health, 2002, 38, 229-234.	0.8	133
340	Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. Pediatric Infectious Disease Journal, 2001, 20, 1083-1086.	2.0	28
341	Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatric Infectious Disease Journal, 2001, 20, 240-246.	2.0	61
342	Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. Archives of Disease in Childhood, 2001, 85, 223-227.	1.9	105

#	Article	IF	CITATIONS
343	Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population?. Epidemiology and Infection, 2000, 124, 239-244.	2.1	143
344	Skin infections and infestations in Aboriginal communities in northern Australia. Australasian Journal of Dermatology, 2000, 41, 139-143.	0.7	182
345	Contrasting Molecular Epidemiology of Group A Streptococci Causing Tropical and Nontropical Infections of the Skin and Throat. Journal of Infectious Diseases, 2000, 182, 1109-1116.	4.0	139
346	Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. International Immunology, 1999, 11, 569-576.	4.0	28
347	Epidemiology and Prevention of Group A Streptococcal Infections: Acute Respiratory Tract Infections, Skin Infections, and their Sequelae at the Close of the Twentieth Century. Clinical Infectious Diseases, 1999, 28, 205-210.	5.8	74
348	Rheumatic chorea in northern Australia: a clinical and epidemiological study. Archives of Disease in Childhood, 1999, 80, 353-358.	1.9	81
349	Mortality due to acute rheumatic fever and rheumatic heart disease in the Northern Territory: a preventable cause of death in Aboriginal people. Australian and New Zealand Journal of Public Health, 1999, 23, 159-163.	1.8	48
350	Outcomes of cardiac valve replacement for rheumatic heart disease in aboriginal Australians. Heart, Lung and Circulation, 1999, 8, 138-147.	0.1	21
351	Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiology and Infection, 1999, 122, 59-65.	2.1	80
352	Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatric Infectious Disease Journal, 1999, 18, 327-332.	2.0	55
353	Acute rheumatic fever (ARF) in non-Aboriginal patients in the Northern Territory. Australian and New Zealand Journal of Medicine, 1998, 28, 63-64.	0.5	1
354	Ability of clinical isolates of group A streptococci to adhere to and invade HEp-2 epithelial cells. Journal of Medical Microbiology, 1998, 47, 899-906.	1.8	17
355	Preventing rheumatic heart disease in Australia. Medical Journal of Australia, 1998, 168, 428-429.	1.7	29
356	Tenâ€year followâ€up of a cohort with rheumatic heart disease (RHD). Australian and New Zealand Journal of Medicine, 1997, 27, 691-697.	0.5	30
357	Clinical Epidemiology of Rheumatic Fever and Rheumatic Heart Disease in Tropical Australia. Advances in Experimental Medicine and Biology, 1997, 418, 233-236.	1.6	23
358	Success of a scabies control program in an Australian Aboriginal community. Pediatric Infectious Disease Journal, 1997, 16, 494-499.	2.0	157
359	Group A streptococcus, pyoderma, and rheumatic fever. Lancet, The, 1996, 347, 1271-1272.	13.7	50
360	Acute rheumatic fever and rheumatic heart disease in the Top End of Australia's Northern Territory. Medical Journal of Australia, 1996, 164, 146-149.	1.7	190

#	Article	IF	CITATIONS
361	An infant with fever and convulsions. European Journal of Pediatrics, 1996, 155, 517-518.	2.7	4
362	A subtle presentation of acute rheumatic fever in remote northern Australia. Australian and New Zealand Journal of Medicine, 1996, 26, 241-242.	0.5	5
363	Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology, 1996, 89, 331-337.	4.4	88
364	Towards Understanding the Pathogenesis of Rheumatic Fever. Scandinavian Journal of Rheumatology, 1996, 25, 127-131.	1.1	25
365	Disseminated, Multiclonal Epstein-Barr Virus-Associated Lymphoproliferative Disease in a Patient with Hematological and Immunological Anomalies Molecular Analysis Correlates with Morphological Appearance. Diagnostic Molecular Pathology, 1995, 4, 39-47–47.	2.1	2
366	Increasing Severity of Invasive Group A Streptococcal Disease in Australia: Clinical and Molecular Epidemiological Features and Identification of a New Virulent M-Nontypeable Clone. Clinical Infectious Diseases, 1995, 21, 1220-1227.	5.8	89
367	SKIN SORES IN ABORIGINAL CHILDREN. Journal of Paediatrics and Child Health, 1995, 31, 563-563.	0.8	18
368	Leuconostoc sepsis in association with continous enteral feeding. Pediatric Infectious Disease Journal, 1994, 13, 816-822.	2.0	25